nodes	percent_of_prediction	percent_of_DWPC	metapath
Clindamycin—Vulvovaginal pain—Capecitabine—esophageal cancer	0.0582	0.0582	CcSEcCtD
Clindamycin—Vaginal pain—Capecitabine—esophageal cancer	0.0582	0.0582	CcSEcCtD
Clindamycin—Superinfection—Capecitabine—esophageal cancer	0.0347	0.0347	CcSEcCtD
Clindamycin—Diarrhoea haemorrhagic—Capecitabine—esophageal cancer	0.0312	0.0312	CcSEcCtD
Clindamycin—Localised oedema—Capecitabine—esophageal cancer	0.0312	0.0312	CcSEcCtD
Clindamycin—Localized exfoliation—Capecitabine—esophageal cancer	0.0292	0.0292	CcSEcCtD
Clindamycin—Oesophageal ulcer—Capecitabine—esophageal cancer	0.0216	0.0216	CcSEcCtD
Clindamycin—Haematochezia—Capecitabine—esophageal cancer	0.0196	0.0196	CcSEcCtD
Clindamycin—Sunburn—Methotrexate—esophageal cancer	0.0194	0.0194	CcSEcCtD
Clindamycin—Taste metallic—Methotrexate—esophageal cancer	0.0184	0.0184	CcSEcCtD
Clindamycin—Prurigo—Capecitabine—esophageal cancer	0.0171	0.0171	CcSEcCtD
Clindamycin—Abscess—Cisplatin—esophageal cancer	0.0135	0.0135	CcSEcCtD
Clindamycin—Bacterial infection—Methotrexate—esophageal cancer	0.0127	0.0127	CcSEcCtD
Clindamycin—Tenderness—Cisplatin—esophageal cancer	0.0122	0.0122	CcSEcCtD
Clindamycin—Ulcer—Cisplatin—esophageal cancer	0.0113	0.0113	CcSEcCtD
Clindamycin—Pain—Carboplatin—esophageal cancer	0.0111	0.0111	CcSEcCtD
Clindamycin—Metrorrhagia—Capecitabine—esophageal cancer	0.011	0.011	CcSEcCtD
Clindamycin—Azotaemia—Methotrexate—esophageal cancer	0.011	0.011	CcSEcCtD
Clindamycin—Vaginal haemorrhage—Capecitabine—esophageal cancer	0.0106	0.0106	CcSEcCtD
Clindamycin—Rash erythematous—Capecitabine—esophageal cancer	0.0103	0.0103	CcSEcCtD
Clindamycin—Body temperature increased—Carboplatin—esophageal cancer	0.0103	0.0103	CcSEcCtD
Clindamycin—Skin exfoliation—Cisplatin—esophageal cancer	0.0102	0.0102	CcSEcCtD
Clindamycin—Fungal infection—Capecitabine—esophageal cancer	0.0102	0.0102	CcSEcCtD
Clindamycin—Vaginal discharge—Methotrexate—esophageal cancer	0.00964	0.00964	CcSEcCtD
Clindamycin—Folliculitis—Methotrexate—esophageal cancer	0.00933	0.00933	CcSEcCtD
Clindamycin—Proteinuria—Capecitabine—esophageal cancer	0.00896	0.00896	CcSEcCtD
Clindamycin—Protein urine present—Capecitabine—esophageal cancer	0.00884	0.00884	CcSEcCtD
Clindamycin—Ulcer—Capecitabine—esophageal cancer	0.00833	0.00833	CcSEcCtD
Clindamycin—Inflammation—Capecitabine—esophageal cancer	0.00812	0.00812	CcSEcCtD
Clindamycin—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.00801	0.00801	CcSEcCtD
Clindamycin—Fungal infection—Methotrexate—esophageal cancer	0.00759	0.00759	CcSEcCtD
Clindamycin—Colitis—Capecitabine—esophageal cancer	0.00756	0.00756	CcSEcCtD
Clindamycin—Candida infection—Capecitabine—esophageal cancer	0.00752	0.00752	CcSEcCtD
Clindamycin—Skin exfoliation—Capecitabine—esophageal cancer	0.00752	0.00752	CcSEcCtD
Clindamycin—Abscess—Methotrexate—esophageal cancer	0.00741	0.00741	CcSEcCtD
Clindamycin—Oesophagitis—Capecitabine—esophageal cancer	0.0072	0.0072	CcSEcCtD
Clindamycin—Cramp muscle—Cisplatin—esophageal cancer	0.00698	0.00698	CcSEcCtD
Clindamycin—Proteinuria—Methotrexate—esophageal cancer	0.00667	0.00667	CcSEcCtD
Clindamycin—Thrombophlebitis—Capecitabine—esophageal cancer	0.0066	0.0066	CcSEcCtD
Clindamycin—Protein urine present—Methotrexate—esophageal cancer	0.00658	0.00658	CcSEcCtD
Clindamycin—Swelling—Capecitabine—esophageal cancer	0.00648	0.00648	CcSEcCtD
Clindamycin—Abdominal discomfort—Cisplatin—esophageal cancer	0.00643	0.00643	CcSEcCtD
Clindamycin—Oliguria—Methotrexate—esophageal cancer	0.00636	0.00636	CcSEcCtD
Clindamycin—Ulcer—Methotrexate—esophageal cancer	0.0062	0.0062	CcSEcCtD
Clindamycin—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.00606	0.00606	CcSEcCtD
Clindamycin—Inflammation—Methotrexate—esophageal cancer	0.00604	0.00604	CcSEcCtD
Clindamycin—Dermatitis bullous—Capecitabine—esophageal cancer	0.00598	0.00598	CcSEcCtD
Clindamycin—Vaginal inflammation—Methotrexate—esophageal cancer	0.00586	0.00586	CcSEcCtD
Clindamycin—Skin exfoliation—Methotrexate—esophageal cancer	0.0056	0.0056	CcSEcCtD
Clindamycin—Vaginal infection—Methotrexate—esophageal cancer	0.00554	0.00554	CcSEcCtD
Clindamycin—Cardiac arrest—Capecitabine—esophageal cancer	0.00544	0.00544	CcSEcCtD
Clindamycin—Dry skin—Capecitabine—esophageal cancer	0.00524	0.00524	CcSEcCtD
Clindamycin—Abdominal pain upper—Capecitabine—esophageal cancer	0.00522	0.00522	CcSEcCtD
Clindamycin—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00515	0.00515	CcSEcCtD
Clindamycin—Flushing—Cisplatin—esophageal cancer	0.00498	0.00498	CcSEcCtD
Clindamycin—Abdominal distension—Capecitabine—esophageal cancer	0.00497	0.00497	CcSEcCtD
Clindamycin—Thrombophlebitis—Methotrexate—esophageal cancer	0.00492	0.00492	CcSEcCtD
Clindamycin—Abdominal discomfort—Capecitabine—esophageal cancer	0.00474	0.00474	CcSEcCtD
Clindamycin—Erythema—Cisplatin—esophageal cancer	0.00467	0.00467	CcSEcCtD
Clindamycin—Dysuria—Capecitabine—esophageal cancer	0.00462	0.00462	CcSEcCtD
Clindamycin—Neutropenia—Capecitabine—esophageal cancer	0.00462	0.00462	CcSEcCtD
Clindamycin—Flatulence—Cisplatin—esophageal cancer	0.0046	0.0046	CcSEcCtD
Clindamycin—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00459	0.00459	CcSEcCtD
Clindamycin—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00451	0.00451	CcSEcCtD
Clindamycin—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00451	0.00451	CcSEcCtD
Clindamycin—Muscle spasms—Cisplatin—esophageal cancer	0.00449	0.00449	CcSEcCtD
Clindamycin—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.0044	0.0044	CcSEcCtD
Clindamycin—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00437	0.00437	CcSEcCtD
Clindamycin—Anaemia—Cisplatin—esophageal cancer	0.00432	0.00432	CcSEcCtD
Clindamycin—Jaundice—Capecitabine—esophageal cancer	0.00429	0.00429	CcSEcCtD
Clindamycin—Urinary tract infection—Capecitabine—esophageal cancer	0.00428	0.00428	CcSEcCtD
Clindamycin—Leukopenia—Cisplatin—esophageal cancer	0.00418	0.00418	CcSEcCtD
Clindamycin—Epistaxis—Capecitabine—esophageal cancer	0.00416	0.00416	CcSEcCtD
Clindamycin—Agranulocytosis—Capecitabine—esophageal cancer	0.00411	0.00411	CcSEcCtD
Clindamycin—Discomfort—Cisplatin—esophageal cancer	0.00393	0.00393	CcSEcCtD
Clindamycin—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00383	0.00383	CcSEcCtD
Clindamycin—Anaphylactic shock—Cisplatin—esophageal cancer	0.00381	0.00381	CcSEcCtD
Clindamycin—Erythema multiforme—Capecitabine—esophageal cancer	0.00374	0.00374	CcSEcCtD
Clindamycin—Thrombocytopenia—Cisplatin—esophageal cancer	0.00373	0.00373	CcSEcCtD
Clindamycin—Flushing—Capecitabine—esophageal cancer	0.00367	0.00367	CcSEcCtD
Clindamycin—Eosinophilia—Methotrexate—esophageal cancer	0.00364	0.00364	CcSEcCtD
Clindamycin—Hypotension—Cisplatin—esophageal cancer	0.00356	0.00356	CcSEcCtD
Clindamycin—Abdominal discomfort—Methotrexate—esophageal cancer	0.00353	0.00353	CcSEcCtD
Clindamycin—Erythema—Capecitabine—esophageal cancer	0.00344	0.00344	CcSEcCtD
Clindamycin—Dysuria—Methotrexate—esophageal cancer	0.00344	0.00344	CcSEcCtD
Clindamycin—Neutropenia—Methotrexate—esophageal cancer	0.00344	0.00344	CcSEcCtD
Clindamycin—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00342	0.00342	CcSEcCtD
Clindamycin—Dyspnoea—Cisplatin—esophageal cancer	0.0034	0.0034	CcSEcCtD
Clindamycin—Flatulence—Capecitabine—esophageal cancer	0.00339	0.00339	CcSEcCtD
Clindamycin—Dysgeusia—Capecitabine—esophageal cancer	0.00337	0.00337	CcSEcCtD
Clindamycin—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00336	0.00336	CcSEcCtD
Clindamycin—Back pain—Capecitabine—esophageal cancer	0.00333	0.00333	CcSEcCtD
Clindamycin—Muscle spasms—Capecitabine—esophageal cancer	0.00331	0.00331	CcSEcCtD
Clindamycin—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00329	0.00329	CcSEcCtD
Clindamycin—Pain—Cisplatin—esophageal cancer	0.00326	0.00326	CcSEcCtD
Clindamycin—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00325	0.00325	CcSEcCtD
Clindamycin—Anaemia—Capecitabine—esophageal cancer	0.00318	0.00318	CcSEcCtD
Clindamycin—Epistaxis—Methotrexate—esophageal cancer	0.00309	0.00309	CcSEcCtD
Clindamycin—Vertigo—Capecitabine—esophageal cancer	0.00309	0.00309	CcSEcCtD
Clindamycin—Leukopenia—Capecitabine—esophageal cancer	0.00308	0.00308	CcSEcCtD
Clindamycin—Agranulocytosis—Methotrexate—esophageal cancer	0.00306	0.00306	CcSEcCtD
Clindamycin—Body temperature increased—Cisplatin—esophageal cancer	0.00301	0.00301	CcSEcCtD
Clindamycin—Hypertension—Capecitabine—esophageal cancer	0.00297	0.00297	CcSEcCtD
Clindamycin—Discomfort—Capecitabine—esophageal cancer	0.0029	0.0029	CcSEcCtD
Clindamycin—Hypersensitivity—Cisplatin—esophageal cancer	0.00281	0.00281	CcSEcCtD
Clindamycin—Erythema multiforme—Methotrexate—esophageal cancer	0.00278	0.00278	CcSEcCtD
Clindamycin—Thrombocytopenia—Capecitabine—esophageal cancer	0.00275	0.00275	CcSEcCtD
Clindamycin—Asthenia—Cisplatin—esophageal cancer	0.00274	0.00274	CcSEcCtD
Clindamycin—Hypotension—Capecitabine—esophageal cancer	0.00263	0.00263	CcSEcCtD
Clindamycin—Diarrhoea—Cisplatin—esophageal cancer	0.00261	0.00261	CcSEcCtD
Clindamycin—Erythema—Methotrexate—esophageal cancer	0.00256	0.00256	CcSEcCtD
Clindamycin—Dysgeusia—Methotrexate—esophageal cancer	0.00251	0.00251	CcSEcCtD
Clindamycin—Dyspnoea—Capecitabine—esophageal cancer	0.00251	0.00251	CcSEcCtD
Clindamycin—Back pain—Methotrexate—esophageal cancer	0.00248	0.00248	CcSEcCtD
Clindamycin—Dyspepsia—Capecitabine—esophageal cancer	0.00247	0.00247	CcSEcCtD
Clindamycin—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00243	0.00243	CcSEcCtD
Clindamycin—Vomiting—Cisplatin—esophageal cancer	0.00242	0.00242	CcSEcCtD
Clindamycin—Fatigue—Capecitabine—esophageal cancer	0.00242	0.00242	CcSEcCtD
Clindamycin—Rash—Cisplatin—esophageal cancer	0.0024	0.0024	CcSEcCtD
Clindamycin—Pain—Capecitabine—esophageal cancer	0.0024	0.0024	CcSEcCtD
Clindamycin—Constipation—Capecitabine—esophageal cancer	0.0024	0.0024	CcSEcCtD
Clindamycin—Dermatitis—Cisplatin—esophageal cancer	0.0024	0.0024	CcSEcCtD
Clindamycin—Anaemia—Methotrexate—esophageal cancer	0.00237	0.00237	CcSEcCtD
Clindamycin—Vertigo—Methotrexate—esophageal cancer	0.0023	0.0023	CcSEcCtD
Clindamycin—Gastrointestinal pain—Capecitabine—esophageal cancer	0.0023	0.0023	CcSEcCtD
Clindamycin—Leukopenia—Methotrexate—esophageal cancer	0.00229	0.00229	CcSEcCtD
Clindamycin—Nausea—Cisplatin—esophageal cancer	0.00226	0.00226	CcSEcCtD
Clindamycin—Urticaria—Capecitabine—esophageal cancer	0.00223	0.00223	CcSEcCtD
Clindamycin—Abdominal pain—Capecitabine—esophageal cancer	0.00222	0.00222	CcSEcCtD
Clindamycin—Body temperature increased—Capecitabine—esophageal cancer	0.00222	0.00222	CcSEcCtD
Clindamycin—Discomfort—Methotrexate—esophageal cancer	0.00216	0.00216	CcSEcCtD
Clindamycin—Anaphylactic shock—Methotrexate—esophageal cancer	0.00209	0.00209	CcSEcCtD
Clindamycin—Hypersensitivity—Capecitabine—esophageal cancer	0.00207	0.00207	CcSEcCtD
Clindamycin—Thrombocytopenia—Methotrexate—esophageal cancer	0.00205	0.00205	CcSEcCtD
Clindamycin—Asthenia—Capecitabine—esophageal cancer	0.00202	0.00202	CcSEcCtD
Clindamycin—Pruritus—Capecitabine—esophageal cancer	0.00199	0.00199	CcSEcCtD
Clindamycin—Hypotension—Methotrexate—esophageal cancer	0.00195	0.00195	CcSEcCtD
Clindamycin—Diarrhoea—Capecitabine—esophageal cancer	0.00192	0.00192	CcSEcCtD
Clindamycin—Dyspnoea—Methotrexate—esophageal cancer	0.00187	0.00187	CcSEcCtD
Clindamycin—Dizziness—Capecitabine—esophageal cancer	0.00186	0.00186	CcSEcCtD
Clindamycin—Dyspepsia—Methotrexate—esophageal cancer	0.00184	0.00184	CcSEcCtD
Clindamycin—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00181	0.00181	CcSEcCtD
Clindamycin—Fatigue—Methotrexate—esophageal cancer	0.0018	0.0018	CcSEcCtD
Clindamycin—Pain—Methotrexate—esophageal cancer	0.00179	0.00179	CcSEcCtD
Clindamycin—Vomiting—Capecitabine—esophageal cancer	0.00179	0.00179	CcSEcCtD
Clindamycin—Rash—Capecitabine—esophageal cancer	0.00177	0.00177	CcSEcCtD
Clindamycin—Dermatitis—Capecitabine—esophageal cancer	0.00177	0.00177	CcSEcCtD
Clindamycin—Headache—Capecitabine—esophageal cancer	0.00176	0.00176	CcSEcCtD
Clindamycin—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00171	0.00171	CcSEcCtD
Clindamycin—Nausea—Capecitabine—esophageal cancer	0.00167	0.00167	CcSEcCtD
Clindamycin—Urticaria—Methotrexate—esophageal cancer	0.00166	0.00166	CcSEcCtD
Clindamycin—Abdominal pain—Methotrexate—esophageal cancer	0.00165	0.00165	CcSEcCtD
Clindamycin—Body temperature increased—Methotrexate—esophageal cancer	0.00165	0.00165	CcSEcCtD
Clindamycin—Hypersensitivity—Methotrexate—esophageal cancer	0.00154	0.00154	CcSEcCtD
Clindamycin—Asthenia—Methotrexate—esophageal cancer	0.0015	0.0015	CcSEcCtD
Clindamycin—Pruritus—Methotrexate—esophageal cancer	0.00148	0.00148	CcSEcCtD
Clindamycin—Diarrhoea—Methotrexate—esophageal cancer	0.00143	0.00143	CcSEcCtD
Clindamycin—Dizziness—Methotrexate—esophageal cancer	0.00138	0.00138	CcSEcCtD
Clindamycin—Vomiting—Methotrexate—esophageal cancer	0.00133	0.00133	CcSEcCtD
Clindamycin—Rash—Methotrexate—esophageal cancer	0.00132	0.00132	CcSEcCtD
Clindamycin—Dermatitis—Methotrexate—esophageal cancer	0.00132	0.00132	CcSEcCtD
Clindamycin—Headache—Methotrexate—esophageal cancer	0.00131	0.00131	CcSEcCtD
Clindamycin—Nausea—Methotrexate—esophageal cancer	0.00124	0.00124	CcSEcCtD
